Beren Therapeutics’Adrabetadex Received FDA Acceptance for infantile-onset Niemann Pick Disease
Beren Therapeutics Announced FDA Acceptance of its New Drug Application for Adrabetadex in Infantile-Onset Niemann-Pick Disease Type C. Beren Therapeutics